Skin Cancer

Latest News

Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its approval by the FDA.
FDA Grants Accelerated Approval to Retifanlimab-dlwr for Merkel Cell Carcinoma

March 22nd 2023

Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.

The biologic license application for cosibelimab for patients with metastatic or locally advanced cutaneous squamous cell carcinoma is supported by findings from a phase 1 study.
BLA for Cosibelimab Submitted to FDA for Management of Metastatic/Advanced Cutaneous SCC

January 5th 2023

Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC
Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC

September 12th 2022

Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.
RP1/Nivolumab Yields Promising Antitumor Activity in Non-Melanoma Skin Cancer

February 26th 2022

Cosibelimab Achieves Promising Responses in Metastatic Cutaneous Squamous Cell Carcinoma
Cosibelimab Achieves Promising Responses in Metastatic Cutaneous Squamous Cell Carcinoma

February 2nd 2022

Video Interviews
Podcasts
On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

More News